Joel Greenbowe
About
Joel Greenbowe is a scholar working on Oncology, Cancer Research and Molecular Biology.
According to data from OpenAlex, Joel Greenbowe has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Cancer Research and 11 papers in Molecular Biology. Recurrent topics in Joel Greenbowe's work include Cancer Genomics and Diagnostics (11 papers), Lung Cancer Treatments and Mutations (10 papers) and RNA modifications and cancer (4 papers). Joel Greenbowe is often cited by papers focused on Cancer Genomics and Diagnostics (11 papers), Lung Cancer Treatments and Mutations (10 papers) and RNA modifications and cancer (4 papers). Joel Greenbowe collaborates with scholars based in United States, South Korea and Israel. Joel Greenbowe's co-authors include Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali, Samuel J. Klempner, Alexa B. Schrock, Kyle Gowen, Sai‐Hong Ignatius Ou, Phil Stephens, Nathan Bahary and Naiyer A. Rizvi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.
In The Last Decade
Joel Greenbowe
18 papers receiving 1.1k citations
Peers
Joel Greenbowe
Kyle Gowen United States
Daygen L. Finch Canada
Siddhartha Devarakonda United States
Jonas Leichsenring Germany
Nicolas Pécuchet France
Angela N. Bartley United States
Edward Arrowsmith United States
Bjarne R. Bartlett United States
Leonie J. Mekenkamp Netherlands
Yasir Y. Elamin United States
Citations per year, relative to Joel Greenbowe Joel Greenbowe (= 1×)
peers
Kyle Gowen
Countries citing papers authored by Joel Greenbowe
Since
Specialization
Citations
This map shows the geographic impact of Joel Greenbowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Greenbowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Greenbowe more than expected).
Fields of papers citing papers by Joel Greenbowe
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Joel Greenbowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Greenbowe. The network helps show where Joel Greenbowe may publish in the future.
Co-authorship network of co-authors of Joel Greenbowe
This figure shows the co-authorship network connecting the top 25 collaborators of Joel Greenbowe. A scholar is included among the top collaborators of Joel Greenbowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Greenbowe. Joel Greenbowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Singhi, Aatur D., Ben George, Joel Greenbowe, et al.. (2019). Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 156(8). 2242–2253.e4.
2.
Goldberg, Michael E., Meagan Montesion, Lauren Young, et al.. (2018). Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. PLoS ONE. 13(11). e0208097–e0208097.
3.
Fabrizio, David, Thomas J. George, Richard F. Dunne, et al.. (2018). Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. Journal of Gastrointestinal Oncology. 9(4). 610–617.
4.
Singhi, Aatur D., Joel Greenbowe, Jon Chung, et al.. (2018). Comprehensive genomic profiling to identify recurrent kinase fusions in pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology. 36(4_suppl). 292–292.
5.
Singhi, Aatur D., Siraj M. Ali, Jill Lacy, et al.. (2017). Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma. Journal of the National Comprehensive Cancer Network. 15(5). 555–562.
6.
Lin, Douglas I., Yakov Chudnovsky, Deborah A. Zajchowski, et al.. (2017). Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type. Gynecologic Oncology. 147(3). 626–633.
7.
Kim, Hyo Song, Minkyu Jung, Sang Joon Shin, et al.. (2017). Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Oncogene. 36(23). 3334–3345.
8.
Lieber, Daniel S., Mark Kennedy, Douglas B. Johnson, et al.. (2017). Abstract B16: Validation and clinical feasibility of a Foundation Medicine assay to identify immunotherapy response potential through tumor mutational burden (TMB). Cancer Immunology Research. 5(3_Supplement). B16–B16.
9.
Lieber, Daniel S., Mark Kennedy, Douglas B. Johnson, et al.. (2017). Abstract 2987: Validation and clinical feasibility of a comprehensive genomic profiling assay to identify likely immunotherapy responders through tumor mutational burden (TMB). Cancer Research. 77(13_Supplement). 2987–2987.
10.
DiBardino, David M., Anjali Saqi, Julia A. Elvin, et al.. (2016). Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma. Clinical Lung Cancer. 17(6). 517–522.e3.
11.
George, Thomas J., Garrett M. Frampton, James Sun, et al.. (2016). Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.. Journal of Clinical Oncology. 34(15_suppl). 3587–3587.
12.
Johnson, Douglas B., Garrett M. Frampton, Matthew J. Rioth, et al.. (2016). Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.. Journal of Clinical Oncology. 34(15_suppl). 105–105.
13.
Lim, Sun Min, Eun Young Kim, Hye Ryun Kim, et al.. (2016). Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. Oncotarget. 7(17). 24172–24178.
14.
Drilon, Alexander, Lu Wang, Maria E. Arcila, et al.. (2015). Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clinical Cancer Research. 21(16). 3631–3639.
15.
Ou, Sai‐Hong Ignatius, Joel Greenbowe, Ziad U. Khan, et al.. (2015). I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Lung Cancer. 88(2). 231–234.
16.
Klempner, Samuel J., Lyudmila Bazhenova, Fadi S. Braiteh, et al.. (2015). Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer. 89(3). 357–359.
17.
Frampton, Garrett M., Siraj M. Ali, Juliann Chmielecki, et al.. (2015). Abstract 1118: Activation of MET via diverse exon 14 skipping mutations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Research. 75(15_Supplement). 1118–1118.
18.
Ou, Sai‐Hong Ignatius, Samuel J. Klempner, Joel Greenbowe, et al.. (2014). Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib. Journal of Thoracic Oncology. 9(12). 1821–1825.
19.
Drilon, Alexander, Lu Wang, Maria E. Arcila, et al.. (2014). Next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in “pan-negative” lung adenocarcinomas (ADC) from patients with no smoking or a light smoking (NS/LS) history.. Journal of Clinical Oncology. 32(15_suppl). 8029–8029.
20.
Rampal, Raajit K., Sean M. Devlin, Jay P. Patel, et al.. (2013). Integrated Genetic Profiling Of JAK2 Wildtype Chronic-Phase Myeloproliferative Neoplasms. Blood. 122(21). 1588–1588.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kyle Gowen Breakdown of academic impact, for papers by Daygen L. Finch Breakdown of academic impact, for papers by Siddhartha Devarakonda Breakdown of academic impact, for papers by Jonas Leichsenring Breakdown of academic impact, for papers by Nicolas Pécuchet Breakdown of academic impact, for papers by Angela N. Bartley Breakdown of academic impact, for papers by Edward Arrowsmith Breakdown of academic impact, for papers by Bjarne R. Bartlett Breakdown of academic impact, for papers by Leonie J. Mekenkamp Breakdown of academic impact, for papers by Yasir Y. Elamin